Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (1605)	6/23/2006 10:46:58 AM
From: rkrw	Read Replies (1) \| Respond to of 1834

Well said!! I saw Lyons at a bio conference, I think it was spring 05. There was a sleep panel. One of the q's presented to the audience and experts was what drug estorra, indiplon, ambien will be the dominant one. Lyons was in the back and shouted "indiplon, indiplon" So not only is he arrogant, he's also obnoxious. <<<He thinks that the next partner’s deal could be equally as strong, if not stronger, than pfe’s.>>> :-) yeah right sure!

To: software salesperson who wrote (1605)	6/23/2006 8:45:36 PM
From: zeta1961	Read Replies (1) \| Respond to of 1834

When did ya'll learn of the 20mg data being used for 15mg dosing? and why was this dose chosen?..If investors didn't find out 'til last month, that would qualify him/PFE for investor lawsuits?..Following from the sidelines..I can't help wondering whether Pfizer got wind of the FDA's long term sentiment..What do ya'll think is NBIX's best chance for survival?.. Does anyone know what's in the insomnia pipe?..Seroquel in low doses is being used by psychiatrists..I find it very concerning that our medical establishment dispenses a drug as complex as these new anti-psychotics in this indication..I'm probably stating the obvious, again :-(